Shattuck Labs downgraded by Citigroup with a new price target
$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/2/2024 | $8.00 → $2.00 | Buy → Neutral | Citigroup |
| 10/2/2024 | Buy → Hold | Needham | |
| 10/1/2024 | Buy → Neutral | H.C. Wainwright | |
| 6/17/2024 | Buy → Neutral | BTIG Research | |
| 8/31/2022 | $12.00 | Buy | BTIG Research |
| 6/1/2022 | $13.00 | Buy | Citigroup |
| 5/2/2022 | $28.00 | Buy | H.C. Wainwright |
– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today reported financial results for the quarter ended September 30, 2024 and provided recent business highlights. "Last mo
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued – – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in a fireside chat and one-on-one meetings at BTIG's Virtual Biotechnology Conference, taking place August 5-6, 2024. Presentation DetailsConference: BTIG Virtual Biotechnology ConferenceFormat: Fireside chat with covering analyst, Kaveri Pohlman, Ph.D.Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Offi
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To
AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously
Needham downgraded Shattuck Labs from Buy to Hold
H.C. Wainwright downgraded Shattuck Labs from Buy to Neutral
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued – – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co
- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group raised the price target for Bread Financial Holdings, Inc. (NYSE:BFH) from $42 to $45. Evercore ISI Group analyst John Pancari upgraded the stock from Underperform to In-Line. Bread Financial shares gained 0.5% to close at $40.84 on Tuesday. See how other analysts view this stock. TD Cowen raised the price target for Ocular Therapeutix, Inc. (NASDAQ:OCUL) from $7 to $11. TD Cowen analyst Tara Bancroft upgraded the stock from Hold to Buy. Ocular Therapeutix shares fell 0.2% to clo
HC Wainwright & Co. analyst Joseph Pantginis maintains Shattuck Labs (NASDAQ:STTK) with a Buy and lowers the price target from $28 to $16.
Citigroup analyst Yigal Nochomovitz maintains Shattuck Labs (NASDAQ:STTK) with a Buy and lowers the price target from $10 to $9.
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)
SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)
SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)
10-Q - Shattuck Labs, Inc. (0001680367) (Filer)
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
8-K - Shattuck Labs, Inc. (0001680367) (Filer)